L-arginine alpha ketoglutarate (1:1) is the equimolar salt of L-arginine and alpha-ketoglutaric acid. The product is identified as CAS 16856-18-1 and may be represented by the formula C₆H₁₄N₄O₂·C₅H₆O₅, giving a calculated molecular weight of 320.30 g/mol. The calculated L-arginine mass fraction is 54.4%, with the remaining 45.6% contributed by alpha-ketoglutaric acid. This distinction matters for label claims because the alpha-ketoglutarate portion contributes to the total formula weight but is not L-arginine. The salt is typically supplied as a white to off-white crystalline powder, a densified direct-compression granulate, or a micronized powder. Supplier model designations for these forms are not harmonized across compendial standards; the certificate of analysis should therefore state particle-size method, loss on drying, assay method, and the exact counterion mass used for calculation. Because no USP, Ph.Eur., or FCC monograph is specific to the 1:1 salt, release testing is based on supplier specifications and general chapters such as USP <731> for loss on drying, USP <281> for residue on ignition, and USP <232> / <233> or ICH Q3D for elemental impurities. The material is generally sold for dietary supplement solid oral dosage forms and is not to be assumed sterile or suitable for parenteral use without additional controls.

Model designations should always specify the 1:1 stoichiometry because L-arginine alpha ketoglutarate can also be offered as a 2:1 salt in some supplier catalogs. The 2:1 material contains two moles of L-arginine per mole of alpha-ketoglutaric acid, giving a higher calculated L-arginine mass fraction and different handling properties. In procurement records, the term “AAKG” is ambiguous unless the stoichiometric ratio is attached. Standard crystalline powder, densified direct-compression granulate, and micronized grade are all sold under supplier-specific model names; the direct-compression grade is not merely a finer powder but a granule designed for tablet feed-frame flow.

How Does the 1:1 Salt Compare with L-Arginine HCl and L-Citrulline in Dry Formulations?

In dry powder blending, the selection between L-arginine salts is often based on calculated L-arginine mass fraction, chloride load, and hygroscopicity. AAKG 1:1 has a calculated L-arginine mass fraction of 54.4%, while L-arginine hydrochloride has 82.7% and L-arginine base has 100.0%. L-citrulline is not an arginine salt and contributes 0.0% arginine by mass, although it is used as a metabolic precursor in dietary supplement formulations. The replacement factor for L-arginine HCl to AAKG 1:1 is 1.52 when maintaining equivalent calculated L-arginine mass; the replacement factor for L-arginine base to AAKG 1:1 is 1.84. These conversion factors are arithmetic and do not establish equivalent clinical response, because dissolution rate, solution pH, and absorption cannot be inferred from mass fraction alone.

The chloride-free nature of AAKG 1:1 may be relevant when a formulation already contains potassium chloride or sodium chloride for electrolyte fortification, where additional chloride from L-arginine HCl can affect the total mineral load. In contrast, L-arginine HCl is often specified when a simple, less hygroscopic crystalline salt is desired and the chloride counterion is acceptable. The alpha-ketoglutarate component of AAKG 1:1 also contributes titratable acid equivalents and can chelate polyvalent metal ions in solution, which is not observed with L-arginine HCl or L-arginine base. Published equilibrium and stability data for the 1:1 salt in multicomponent premixes are limited; therefore, forced degradation and compatibility testing under controlled temperature and humidity are required before a commercial blend is locked.

Methods for incoming identification often include FTIR and powder X-ray diffraction. The 1:1 salt shows characteristic carboxylate bands from alpha-ketoglutarate that are absent in L-arginine HCl and L-arginine base. Ion chromatography can confirm the absence of chloride in AAKG 1:1; this is useful when a producer is replacing L-arginine HCl and needs to verify the final mineral load. X-ray powder diffraction distinguishes the crystalline forms because the 1:1 salt has its own lattice parameters and is not a physical mixture of L-arginine and alpha-ketoglutaric acid. Reference diffractograms should be requested from the supplier and retained for change control.

In a production-scale dry blending sequence, AAKG 1:1 is usually charged after a portion of the diluent has been pre-blended with fumed silica. The sequence reduces electrostatic wall adhesion in stainless-steel V-blenders and bin blenders. Blenders are commonly run at 10 to 15 rpm for 15 to 20 minutes; the required time to blend uniformity is established by sampling and assay under a validated protocol rather than by fixed rule. At relative humidity above 60%, the powder surface begins to absorb water, and caking can occur if the headspace is not conditioned. Pre-drying in a fluid-bed dryer with inlet air at 40°C until loss on drying falls below 1.0% is a common corrective action. Direct-compression premixes often contain 0.5 to 2.0 wt% fumed silica or calcium silicate; flow-aid levels above 2.0 wt% can produce hydrophobic regions that slow tablet disintegration under USP <701>. The moisture content after blending should be verified by Karl Fischer titration or USP <921> Method 1a because ambient humidity during transfer can reverse the drying step.

Particle-size distribution affects segregation in multi-ingredient premixes. A coarse standard powder with D₉₀ above 200 µm can segregate from finely milled flavoring or sweetener components during bin discharge; a micronized grade improves suspension uniformity but increases dust exposure. Sieve analysis is performed under USP <786> or ISO 2591-1, and the acceptance band is set to the mixer type and transfer distance. For direct-compression feeding, the densified model is generally used because it reduces bridging in the hopper and maintains die fill consistency.

When Direct Compression Is Preferred Over Capsule Filling

Direct compression of AAKG 1:1 requires a densified supplier model because un-milled crystalline powder can exhibit poor flow and low bulk density in high-speed feed frames. A rotary tablet press with pre-compression is typically used; the pre-compression force is set at approximately 20% of the main compression force to remove air and reduce lamination. Target tablet hardness is usually 6 to 8 kp for standard round tooling, and friability is monitored according to USP <1216> with a maximum of 1.0%. Weight variation is evaluated under USP <905>. Tablet press speed must be adjusted to the granulation flow; high shear in the feed frame can create fines that change ejection force and increase the risk of picking or sticking to upper punches. Compression zones should be maintained at relative humidity below 60% because the salt can hydrate at the tablet surface if the powders are stored in open hoppers.

For capsule filling, a dosator or tamping-style machine may require different fill density adjustments than crystalline L-arginine HCl. The bulk and tapped densities of AAKG 1:1 are reported on the supplier certificate under USP <616>; these values change with residual moisture and particle-size distribution. Capsule blends are often pre-sieved through a 0.8 mm screen to break agglomerates before filling. However, published comparative tableting data for AAKG 1:1 in a standardized excipient matrix remain limited, so the compression and ejection parameters are developed experimentally for each supplier grade. Dissolution or disintegration of the finished dosage form is evaluated under USP <711> or USP <2040> as appropriate for the label claim.

Raw material release testing for AAKG 1:1 usually includes identification, assay, water content, residue on ignition, elemental impurities, and residual solvents. Because the salt is a stoichiometric adduct, assay results should state whether the method quantifies intact salt, L-arginine content, or alpha-ketoglutaric acid content. A non-aqueous titration may measure only the basic L-arginine component; HPLC with UV or charged aerosol detection can separate the alpha-ketoglutarate anion. When assay is expressed as intact salt on dried basis, the supplier limit is commonly 98.0% to 102.0%. If the assay is expressed as L-arginine, the specification must be adjusted to the calculated 54.4% mass fraction and verified with a reference method.

These release controls are not a demonstration of product efficacy or clinical performance. They define the quality of the raw material entering the mixing operation. If the material is intended for sterile or preserved aqueous dosing, additional bioburden, endotoxin, and preservative efficacy testing are required; standard dietary supplement grades are not manufactured under aseptic conditions. In the United States, finished dietary supplement manufacturing is subject to 21 CFR Part 111, and product labels must comply with 21 CFR 101.36 where applicable. Suppliers should provide REACH registration or equivalent for EU use and confirm that the material is not classified under CLP. For food additive applications outside dietary supplements, regulatory status should be verified separately because the salt may not be listed for general food use in all jurisdictions.

Operational Boundaries for Bulk Storage and Aqueous Dispensing

The main bulk-storage boundary is moisture control. Packaged AAKG 1:1 should be stored in a dry area at or below 25°C with relative humidity below 60%. Once a drum is opened, the remaining product should be re-sealed under dry nitrogen or placed in a dessicant-lined container because the powder can absorb atmospheric water within a single shift. Aqueous stock solutions should be prepared at 20°C to 25°C and used within the working day unless a preservative system and pH control are validated. The alpha-ketoglutarate moiety can chelate polyvalent metal ions, so prolonged contact with unlined carbon steel is avoided; 316L stainless steel or high-density polyethylene equipment is preferred. The salt should not be dry-mixed with strong oxidizing agents, strong acids, or aldehydes. With reducing sugars under heated drying, carbonyl–amine condensation can generate brown Maillard-type products and reduce available arginine. Thermal stress above 40°C during drying should be avoided unless forced degradation data demonstrate stability, because the alpha-keto acid component may be sensitive to prolonged heating. Hot water or steam washdown is not recommended for spilled powder; dry vacuum recovery with a HEPA-filtered collector is used to prevent creating a wet alkaline film on equipment.

For dietary supplement powder formulations, AAKG 1:1 is added at the mass fraction required to deliver a target calculated L-arginine equivalent. A dosage form designed to contain 3.0 g of L-arginine base would require 5.52 g of AAKG 1:1 if the conversion factor 1.84 is used. The equivalent L-arginine HCl input would be 3.63 g. These calculations are for mass balance only and do not imply interchangeable absorption or physiological effect. If the 2:1 salt is accidentally purchased and treated as 1:1, the delivered arginine mass will be overestimated; sample identification should include the stoichiometric ratio and preferably FTIR reference authentication. Published data comparing the salt with other arginine sources in the same finished matrix remain limited, so formulators should not extrapolate from single-dose studies without matrix-specific compatibility data.